ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

ClinicalTrials.gov ID: NCT03703297

Public ClinicalTrials.gov record NCT03703297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Study identification

NCT ID
NCT03703297
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
730 participants

Conditions and interventions

Interventions

  • Durvalumab Drug
  • Placebo Other
  • Tremelimumab Drug

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 26, 2018
Primary completion
Jan 14, 2024
Completion
Oct 22, 2026
Last update posted
Nov 20, 2025

2018 – 2026

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
Research Site Tucson Arizona 85715
Research Site Santa Rosa California 95403
Research Site New Haven Connecticut 06510
Research Site Fort Myers Florida 33901
Research Site Orange City Florida 32763
Research Site St. Petersburg Florida 33705
Research Site Marietta Georgia 30060
Research Site Hines Illinois 60141
Research Site Fort Wayne Indiana 46804
Research Site Muncie Indiana 47303
Research Site Lexington Kentucky 40536
Research Site Annapolis Maryland 21401
Research Site Baltimore Maryland 21287
Research Site Towson Maryland 21204
Research Site Boston Massachusetts 02114
Research Site Detroit Michigan 48201
Research Site Grand Rapids Michigan 49503
Research Site Minneapolis Minnesota 55407
Research Site Summit New Jersey 07902
Research Site New Hyde Park New York 11042
Research Site Chapel Hill North Carolina 27599
Research Site Portland Oregon 97239
Research Site Philadelphia Pennsylvania 19111
Research Site Pittsburgh Pennsylvania 15212
Research Site Sioux Falls South Dakota 57104
Research Site Chattanooga Tennessee 37404
Research Site Nashville Tennessee 37203
Research Site Nashville Tennessee 37232
Research Site Dallas Texas 75390
Research Site Kennewick Washington 99336
Research Site Tacoma Washington 98405
Research Site Charleston West Virginia 25304
Research Site Huntington West Virginia 25701
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 149 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03703297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03703297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →